JP2024521861A5 - - Google Patents

Info

Publication number
JP2024521861A5
JP2024521861A5 JP2023573437A JP2023573437A JP2024521861A5 JP 2024521861 A5 JP2024521861 A5 JP 2024521861A5 JP 2023573437 A JP2023573437 A JP 2023573437A JP 2023573437 A JP2023573437 A JP 2023573437A JP 2024521861 A5 JP2024521861 A5 JP 2024521861A5
Authority
JP
Japan
Application number
JP2023573437A
Other languages
Japanese (ja)
Other versions
JP2024521861A (ja
JPWO2022248940A5 (https=
Filing date
Publication date
Priority claimed from US17/334,158 external-priority patent/US20220389104A1/en
Application filed filed Critical
Publication of JP2024521861A publication Critical patent/JP2024521861A/ja
Publication of JPWO2022248940A5 publication Critical patent/JPWO2022248940A5/ja
Publication of JP2024521861A5 publication Critical patent/JP2024521861A5/ja
Pending legal-status Critical Current

Links

JP2023573437A 2021-05-28 2022-05-27 抗cd127剤を投与することによってcd127陽性がんを処置する方法 Pending JP2024521861A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/334,158 2021-05-28
US17/334,158 US20220389104A1 (en) 2021-05-28 2021-05-28 Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
PCT/IB2022/000365 WO2022248940A1 (en) 2021-05-28 2022-05-27 Method for treating cd127-positive cancers by administering an anti-cd127 agent

Publications (3)

Publication Number Publication Date
JP2024521861A JP2024521861A (ja) 2024-06-04
JPWO2022248940A5 JPWO2022248940A5 (https=) 2025-06-03
JP2024521861A5 true JP2024521861A5 (https=) 2025-06-03

Family

ID=82701915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573437A Pending JP2024521861A (ja) 2021-05-28 2022-05-27 抗cd127剤を投与することによってcd127陽性がんを処置する方法

Country Status (5)

Country Link
US (1) US20220389104A1 (https=)
EP (1) EP4347043A1 (https=)
JP (1) JP2024521861A (https=)
CN (1) CN117769435A (https=)
WO (1) WO2022248940A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925955B (zh) * 2022-12-30 2025-09-26 浙江正熙生物技术有限公司 一种抗cd127抗体及其制备方法和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618829A (en) 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
AU691820B2 (en) 1993-07-15 1998-05-28 Cancer Research Campaign Technology Limited Prodrugs of protein tyrosine kinase inhibitors
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
HU228446B1 (en) 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001000214A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
JP2003503351A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Srcキナーゼ阻害化合物
AU5636900A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
DE60023926T2 (de) 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
AU778042B2 (en) 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
HRP20020349A2 (en) 1999-10-19 2004-02-29 Merck & Co Inc Tyrosine kinase inhibitors
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
ATE316088T1 (de) 2001-06-22 2006-02-15 Merck & Co Inc Tyrosin-kinase inhibitoren
WO2003011836A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003020276A1 (en) 2001-08-30 2003-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
MX339083B (es) * 2010-01-28 2016-04-01 Glaxo Group Ltd Proteinas de enlace a cd127.
EP2955196A1 (en) * 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
WO2016059220A1 (en) * 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
WO2016109415A1 (en) * 2014-12-30 2016-07-07 Celgene Corporation Anti-cd47 antibodies and uses thereof
WO2017005919A1 (en) * 2015-07-08 2017-01-12 Biomedical Research Foundation Of The Academy Of Athens Novel compounds for use in treating or preventing cancerous diseases
EP3355875B1 (en) * 2015-10-01 2021-09-29 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
AU2016335750B2 (en) * 2015-10-07 2023-05-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
WO2017149394A1 (en) * 2016-02-29 2017-09-08 Ose Immunotherapeutics Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment
IL301786B2 (en) * 2016-10-28 2025-09-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
DK3551664T3 (da) 2016-12-09 2021-05-03 Ose Immunotherapeutics Antistoffer og polypeptider rettet mod cd127
US11008395B2 (en) 2019-01-22 2021-05-18 Bristol Myers-Squibb Company Antibodies against IL-7R alpha subunit and uses thereof

Similar Documents

Publication Publication Date Title
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13149U (https=)
BY13157U (https=)
BY13135U (https=)
BY13137U (https=)
BY13140U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
BY23968C1 (https=)